Tag Archive for: Wuxi Biologics

samsung_biologics_webSamsung Biologics
CDMO

Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal

Consolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, Samsung Biologics aims to strengthen its position in the fast-growing market for complex biopharmaceuticals.

Read more